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ABSTRACT
Brown adipose tissue (BAT) has recently emerged as a novel target for obesity treatment
and prevention. In contrast to the lipid storing function of white adipocytes, brown adipocytes
are responsible for dissipating energy as heat, a process involving uncoupling protein 1 (UCP1).
Soluble epoxide hydrolase (sEH) is a cytosolic enzyme that converts epoxy fatty acids (EpFAs)
into less active diols. By stabilizing endogenous EpFAs, potent small molecule sEH inhibitors
have been shown to be beneficial for many diseases. Several recent studies have reported that
sEH inhibitors can improve diet-induced metabolic disorders, possibly by upregulating UCP1
expression. In the current study, we sought to investigate the mechanisms by which the sEH
inhibition affects brown adipocytes using trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]benzoic acid (t-AUCB). The effects of t-AUCB on murine brown adipocyte differentiation were
evaluated by lipid accumulation and expression of brown adipocyte marker genes.
PPARα[alpha] and PPARγ[gamma] activation by t-AUCB was measured by their respective
transactivation assays. The roles of PPARs were further studied by pharmacological antagonism
and knockdown experiments. Finally, the mechanisms of t-AUCB were explored in BAT derived
sEH wildtype (WT) and knockout (KO) stromal cells. We report that sEH expression was
increased during murine brown adipocyte differentiation. t-AUCB dose-dependently promoted
brown adipocyte differentiation. Moreover, we demonstrate that t-AUCB activated
PPARα[alpha], but not PPARγ[gamma]. t-AUCB-induced upregulation of thermogenic genes
Ucp1, Pgc-1a, and Cidea and the general differentiation marker Fabp4 was significantly
attenuated by the antagonist of PPARα[alpha], GW6471 and specific knockdown of Pparα. In
contrast, upregulation was only partially attenuated by the antagonist of PPARγ[gamma],
iv

GW9662, and specific knockdown of Pparg. We also show that t-AUCB activation of
PPARα[alpha] occurs regardless of sEH presence. Our findings suggest that PPARα[alpha],
more so than PPARγ[gamma], plays an important role in t-AUCB’s effects on brown
adipogenesis and that these effects may be independent of sEH.
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CHAPTER I
INTRODUCTION
Obesity has become an epidemic, with more than 2.8 million people dying each year due
to the comorbidities associated with being overweight or obese [1]. Obesity is characterized by
the accumulation of excess white adipose tissue (WAT) which is a subclass of adipose tissue that
stores energy as fat [2]. In contrast, brown adipose tissue (BAT) uses energy to produce heat [3].
It was previously thought that metabolically active BAT was only present in infants; however,
studies have now found BAT to be present in small amounts in adult humans [2]. BAT is now
being studied as a potential therapeutic target for the treatment of obesity and related metabolic
diseases [3].
BAT prevalence has been negatively correlated with body mass index and body fat
content [4, 5]. Additionally, BAT activation has been seen to improve insulin sensitivity,
regulate glucose homeostasis, and accelerate triglyceride clearance [6, 7]. The possibility of
enhancing energy-wasting and metabolic function through BAT activity has prompted extensive
research. Several nutritional and pharmacological factors contributing to BAT development and
activity by various mechanisms have been identified, but the search continues for safer and more
effective options [8, 9].
Soluble epoxide hydrolase (sEH) is a cytosolic enzyme that converts epoxy fatty acids
(EpFAs) to diols, typically reducing their biological activity [10, 11]. sEH expression has been
found to be positively correlated with body weight in mouse and human adipose tissue [12]. sEH
inhibitors (sEHIs) have been shown to be beneficial for many disease states [13]. The inhibition
or knockout of sEH in cell and animal studies have proven effective in ameliorating obesity1

related metabolic disorders [14]. While the potential for sEH inhibition to promote weight loss
and directly combat obesity is unclear, it has been shown to activate BAT and prevent weight
gain in a high-fat diet mouse model [15, 16]. Many different sEHIs have been developed and
found to be effective in various species and physiologies [17]. t-AUCB (trans-4-[4-(3adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid) is an especially promising sEHI with
superior solubility and stability as well as high bioavailability and potency across species [18].
sEHIs have entered human trials have and have, so far, been determined to be safe [19, 20]. The
exact mechanisms of the sEHIs are largely unknown. In most studies, sEHI effects have been
attributed to the stabilization of endogenous EpFAs, particularly EETs (epoxyeicosatrienoic
acids) [11, 13, 21]. sEHIs were designed to mimic EETs [22], which are known peroxisome
proliferator-activated receptor alpha (PPARα) [23], and gamma (PPARγ) [24] ligands. Two
sEHIs, CUDA (N-cyclohexyl-N'-dodecanoic acid urea) and AUDA, have been found to directly
activate PPARα, but not PPARδ or PPARγ [25]. The PPARs are especially significant to our
research because of their role in adipogenesis. The objective of this thesis is to study the
mechanisms by which the sEH inhibitor t-AUCB acts on brown preadipocytes, specifically the
role of PPARα and PPARγ. The results presented add to our understanding of t-AUCB and its
therapeutic potential for obesity and related metabolic disease.
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CHAPTER II
LITERATURE REVIEW
2.1 Brown Adipose Tissue: Function, Development, Metabolic Impact, and Regulation
2.1.1. Brown Adipose Tissue Function
Brown adipose tissue (BAT) is a thermoregulatory organ that is essential to non-shivering
thermogenesis in response to cold exposure. In BAT, chemical energy can be converted to heat
via uncoupling protein 1 (UCP1) present in the mitochondria, which are particularly abundant in
BAT. UCP1 uncouples the electron transport chain from adenosine triphosphate (ATP)
production, resulting in energy dissipation and heat production and thereby increased energy
expenditure. UCP1-mediated thermogenesis relies on oxidative metabolism with lipids as the
predominant energy source, but BAT also actively takes up glucose [3].
The development of BAT is thought to be crucial in the evolutionary success of
mammals, as thermogenesis increases neonatal survival and allows mammals to adapt to cold
environments [3]. BAT is found in specific locations in the body [3]. In rodents, BAT depots can
be found in the interscapular, axillary, perirenal, and periaortic regions [3]. Human BAT has
been identified in similar areas, with depots in the supraclavicular, cervical, and paraspinal
regions [26]. BAT is only present in small amounts in adult mammals and to a lesser extent in
obese individuals [27].
Although thermogenesis is the most studied function of BAT, recent findings reveal BAT
involvement in triglyceride clearance, glucose disposal, secretion of signal molecules, and
inflammation [7, 28-30]. For example, it was found that cold-induced BAT activity in mice
decreases plasma triglyceride levels due to increased turnover of triglyceride-rich lipoproteins
3

and uptake of lipids into BAT through activation of CD36, a cell-surface fatty acid translocase
[7]. BAT also serves as a major organ for glucose disposal in these mice, particularly the obese
mice [7].
BAT also functions as a secretory organ, which may contribute to systemic consequences
of BAT activity that are currently being explored [31] [28, 32]. Many regulatory molecules
produced by BAT, called brown adipokines or batokines, have been identified such as fibroblast
growth factor 21 (FGF21), interleukin 6 (IL-6), neuregulin 4 (NRG4), vascular endothelial
growth factor A (VEGFA), and insulin-like growth factor 1 (IGF1) [28]. The systemic roles of
batokines and the potential to take advantage of such molecules for pharmacological intervention
are being researched extensively [33-35]
Additionally, BAT has been suggested to have an anti-inflammatory function [29, 30,
36]. During high-fat feeding in an obese state, immune cells and macrophages accumulate in
WAT, triggering inflammation [29]. Under similar conditions, BAT does not appear to be
infiltrated by macrophages, which may be due to the ability of BAT to quickly use free fatty
acids and avoid lipotoxicity [29]. It was also found that macrophages in BAT do not share the
same chemokine and cytokine expression as those in WAT, indicating that the microenvironment
of BAT could be anti-inflammatory as opposed to the pro-inflammatory microenvironment of
WAT [30, 36].
2.1.2. Brown Adipose Tissue Development
Brown adipocytes are derived from Myf5-expressing cells which are also the precursor
for skeletal muscle cells and a subpopulation of white adipocytes [37, 38]. These cells develop to
brown preadipocytes which then undergo differentiation to brown adipocytes [27]. BAT
4

development has been reported to be under the control of several transcriptional regulators, but
peroxisome proliferator-activated receptor gamma (PPAR) is the main transcription factor that
is required under every circumstance for both white and brown adipocyte development [39].
PPAR is a nuclear hormone receptor expressed mainly in white and brown adipose tissue [40].
Multiple levels of regulation of PPAR allow for targeting of brown adipocyte-specific
transcription [39]. Three PPAR isoforms that have highly conserved DNA-binding domains but
more diverse ligand-binding domains have been identified as a subfamily of nuclear hormone
receptors – PPARα, PPARβ/δ and PPARγ [40]. While PPARγ strongly induces adipogenesis and
is the predominant PPAR isoform involved in this process, PPARα activation can also induce
significant adipogenesis [40].
The association of PPAR with other key regulators of brown adipogenesis, including
PRD1-F1-RIZ1 homologous domain containing 16 (PRDM16) and PPARγ co-activator 1 alpha
(PGC-1α), allows for selective regulation of adipogenic and thermogenic genes. PRDM16 has
been shown to be responsible for controlling whether the Myf5-expressing progenitor cells
become myocytes or brown adipocytes [41]. Overexpression of PRDM16 was found to convert
myocytes into brown adipocytes [42]. Additionally, PRDM16 expression in adipose tissue
induced thermogenic gene expression [42]. PRDM16 binds to other transcriptional regulators
such as CCAAT/enhancer-binding protein beta (C/EBP-β), which induces PPARγ and PGC-1α
expression in preadipocytes [41]. PRDM16 then binds PPARγ and PGC-1α and recruits the
PPARγ transcription complex to the promoter regions of brown adipogenic and thermogenic
genes [41].
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PGC-1α is a cold-induced cofactor of PPARγ involved in thermogenic gene expression
that is also a downstream target of the protein kinase A (PKA) – cyclic AMP – responsive
element-binding protein 1 (CREB) signaling pathway and is post-transcriptionally controlled via
phosphorylation [43]. PGC-1α interacts with PPARγ and directly induces UCP1 expression [44].
PGC-1α also acts as the primary regulator of multiple pathways related to mitochondrial
biogenesis and thermogenesis [45].
2.1.3. Metabolic Impact of Brown Adipose Tissue
BAT is currently under investigation for its therapeutic potential in obesity and metabolic
disease. In 1983, Rothwell and Stock predicted that in humans, stimulation of just a small
amount of BAT, only 40 to 50 grams, could utilize up to 20% of an individual’s daily energy
expenditure [46]. Imaging studies in both mice and humans have shown that BAT mass is
negatively correlated with body mass index and adiposity [4, 5]. In humans, there is some
evidence of small amounts of fat mass loss due to increases in energy expenditure related to BAT
[47]. However, studies of BAT activation in relation to weight loss in humans have overall been
inconclusive [6, 48-50]. Inconsistencies in these studies can likely be attributed to variability in
experimental protocols, type of intervention, measurement of BAT mass and activity, and human
subjects.
In addition to its potential contribution to energy expenditure, BAT has been shown to
have systemic impacts on processes such as glucose and lipid metabolism [6, 31, 51]. Free fatty
acids (FFA) serve as the main substrate for BAT [3]. In rodents, BAT activation appears to
enhance triglyceride clearance, reduce high cholesterol, and protect from atherosclerosis [7, 52].
In humans who underwent 5-8 hours of non-shivering cold exposure, BAT volume was found to
6

be significantly correlated with cold-induced increases in FFA oxidation, whole-body lipolysis,
and triglyceride-FFA cycling as measured by stable isotope tracers and indirect calorimetry [31].
Cold exposure also led to increased plasma FFA and glycerol concentrations with no differences
in plasma concentrations of triglycerides or cholesterol [31]. Fasting plasma concentrations of
very-low-density lipoprotein (VLDL) cholesterol and triglycerides were decreased on the day
after participants endured cold exposure [31]. These results suggest a possible metabolic benefit
of stimulated BAT to induce lipid mobilization from adipose tissue to be used as BAT substrate
for thermogenesis, as well as long-term benefits to lipid metabolism.
BAT also appears to have beneficial effects on glucose metabolism. BAT mass/activity
has been seen to be lower in diabetic than non-diabetic individuals [53]. Using [18F]FDG to trace
glucose uptake and [15O]H2O to measure BAT respiration and determine perfusion rate, it was
found that cold exposure (2 hours at 17°C ambient temperature followed by intermittent
placement of one foot in 8°C water ) induced a 12-fold increase in glucose uptake rate in human
BAT accompanied by a doubling in BAT perfusion (indicative of thermogenesis) with no
changes in glucose uptake rate in subcutaneous WAT, visceral adipose tissue, or skeletal muscle
[51]. Another human study by Chondronikola et al. reported similar findings of cold exposure (58 hours at 19°C ambient temperature while wearing a Cool Flow vest and blanket that decreased
from 20°C until the subject was shivering and was then maintained at 1°C above shivering)
resulting in increased [18F]FDG uptake in BAT but not in the liver, visceral adipose tissue,
subcutaneous adipose tissue, or skeletal muscle [6].
Chondronikola et al. also determined, using PET/CT and indirect calorimetry, that the
observed cold-induced glucose uptake in BAT significantly increased whole-body glucose
7

disposal [6]. The authors calculated that BAT, if able to remain chronically active, could dispose
of about 23 grams of glucose per day [6]. Furthermore, the same cold-exposure conditions to
induced BAT activation during hyperinsulinemia resulted in increases glucose disposal and
insulin sensitivity as compared to hyperinsulinemic conditions in individuals without detectable
BAT [6].
2.1.4 Regulators of Brown Adipose Tissue
One regulator of brown adipose tissue is cold exposure. Cold temperatures are sensed by
certain transient receptor potential (TRP) channels expressed by nerve terminals [54]. These
channels initiate signaling to the hypothalamus which then increases sympathetic signaling to
BAT [55]. BAT is innervated by an abundance of nerve endings that release norepinephrine
upon sympathetic stimulation [56]. The standard model of regulation of BAT thermogenesis
begins with norepinephrine binding to β3-adrenergic receptors (β3-ARs) on the membrane of the
brown adipocytes which causes activation of adenylyl cyclase and subsequent cyclic AMP
(cAMP) production [57]. cAMP activates PKA which phosphorylates adipose tissue triglyceride
lipase (ATGL) resulting in increased lipolysis within the adipocytes [57]. The released FFA then
activate UCP1 [57]. However, this model has been questioned due to the observation that a lack
of ATGL or the ATGL-activating protein CGI-58 within brown adipocytes in mice had no effect
on non-shivering thermogenesis [58, 59]. Alternative models may be necessary to explain how
β3-AR agonists can activate UCP-1 without the intracellular release of FFA.
In addition to cold, an overwhelming number of very diverse factors have been proposed
to regulate brown adipose tissue [9, 57]. Only a small selection of nutritional and
pharmacological factors will be discussed here.
8

2.1.4.1 Capsaicin and Capsinoids
Some of the most studied nutritional regulators of BAT, capsaicin and capsinoids, are
components found in certain peppers that have been shown to increase thermogenesis in mice
and humans [60, 61]. In mice, treatment with a high-fat diet (HFD) containing capsinoids at a
concentration of 0.3% (weight for weight) for 8 weeks with or without mild cold exposure (17
°C) resulted in significantly less body weight gain in the ambient temperature (25 °C) capsinoidtreated mice as compared to the ambient temperature vehicle-treated mice [60]. Furthermore,
while cold exposure resulted in significantly less weight gain than ambient temperature
regardless of capsinoid treatment, the cold-exposed, capsinoid-treated mice gained less weight
than the cold-exposed vehicle-treated mice, indicating a synergistic effect of capsinoids and cold
exposure [60]. Thermoneutral conditions of 30 °C resulted in the attenuation of the anti-obesity
effect of capsinoids [60]. Under 17 °C conditions, the capsinoid-treated mice also had
significantly lower fasting plasma concentrations of glucose and insulin and improved glucose
tolerance and insulin sensitivity as compared to vehicle-treated mice and mice kept at ambient
temperature [60].
In humans, oral ingestion of a single 9 mg dose of capsinoids was reported to induce a
slight but significant increase in energy expenditure in response to cold exposure (19 °C) in
individuals with metabolically active BAT but not in individuals with undetectable BAT as
measured by [18F]FDG-PET [61]. Meta-analyses reveal evidence for the therapeutic potential of
capsinoids and capsaicin in weight management; however, the thermogenic effects are small and
long-term effects are uncertain [62]. It is likely that capsinoids share the same mechanism of
action for promoting BAT thermogenesis in humans as has been described in mice – activation
9

of transient receptor potential vanilloid type 1 (TRPV1) channels in the gastrointestinal tract,
which leads to activation the sympathetic nervous system [63]. In mice that lack all three forms
of β-adrenergic receptors, the anti-obesity effects of capsinoids were eliminated, suggesting the
necessity of the β-adrenergic pathway in capsinoid-stimulated thermogenesis, which could
include both direct adrenergic effects and indirect effects via sympathetic nervous system
activation [60].
2.1.4.2 Fish Oil
Fish oil is also a dietary component with growing evidence of involvement in BAT
regulation. In rats, fish oil supplementation (200 g/kg body weight for 21 days) has been found to
increase Ucp1 mRNA expression in interscapular BAT (iBAT) [64]. Replacement of dietary
monounsaturated fats with docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), or a
mixture of DHA and EPA, which are major polyunsaturated fatty acids (PUFA) in fish oil, has
been seen to affect mitochondrial and thermogenic activity in the iBAT of rats, with EPA
increasing number of mitochondria and DHA or a mixture of DHA and EPA increasing
mitochondrial size and activity [65]. In mice, an HFD containing 12% fish oil for 8 weeks was
seen to increase mRNA expression of the thermogenic genes Adrb3, Pgc-1a, and Ucp1 in iBAT,
prevent diet-induced weight gain, improve glucose tolerance and triglyceride concentrations, and
reduce the expression of pro-inflammatory genes [66]. Pgc-1a, carnitine palmitoyltransferase 1
B (Cpt1b), and Prdm16 expression have also been reported to increase in mouse iBAT in
response to a fish oil-enriched diet (2.4% DHA- or EPA-enriched fish oil), with no significant
changes in cell death-inducing DFFA-like effector A (Cidea) or Fgf21 [67]. While some benefits
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of fish oil have been reported in humans, such as improved lipid profiles and glucose
homeostasis, little information is available on the role of BAT in these effects [68].
Fish oil may elicit its effect in a similar way as capsaicin and the capsinoids with a
mechanism involving TRPV1 and activation of the sympathetic nervous system [67]. In TRPV1
knockout (KO) mice, the anti-obesogenic effects and improvements in plasma glucose and
triglyceride concentrations seen with fish oil supplementation in wild-type (WT) mice were lost
[67]. Moreover, fish oil resulted in increased norepinephrine in the urine and upregulation of β3AR mRNA in iBAT in WT mice, but not TRPV1 KO mice, and treatment with a β3-AR
antagonist prevented the fish-oil induced increase in Ucp1, suggesting that TRPV1 mediates
sympathetic nervous system activation by fish oil, leading to β3-AR activation and subsequent
induction of UCP1 and thermogenesis [67]. Elements of fish oil may impact BAT by other
mechanisms. For example, EPA has been shown to induce BAT thermogenesis via FFA receptor
4 (FFAR4) [69].
2.1.4.3 Resveratrol
Another well-known nutritional factor implemented in BAT regulation is resveratrol, a
polyphenolic compound found in the weed Polygonum cuspidatum and in trace amounts in foods
such as red wine and peanuts [70]. High doses of resveratrol of around 400 mg/kg body weight
have been shown to decrease weight gain in HFD-fed mice [71, 72]. Increased basal energy
expenditure, cold tolerance, mitochondrial volume and DNA, and PGC-1α activity in BAT of
mice treated with resveratrol have also been reported [71]. Resveratrol has also been studied in
non-human primates (gray mouse lemurs), where it was observed to significantly increase resting
energy expenditure [73, 74]. The mechanisms of these effects likely involve AMPK (5'
11

adenosine monophosphate-activated protein kinase), SIRT1 (Sirtuin 1), and PGC-1α [72].
Resveratrol treatment has been seen to increase Sirt1 gene expression in mouse BAT which may
then deacetylate and increase PGC-1α activity [71, 75]. An increase in phospho-AMPKα was
observed in resveratrol treated mice without a difference in total AMPKα, suggesting that
resveratrol’s effects on BAT are associated with AMPK activation [72]. Also, in differentiated
mouse iBAT stromal vascular cells, upregulation PRDM16, UCP1, Cytochrome C, and PDH
(pyruvate dehydrogenase) by resveratrol was attenuated by AMPKα1 inhibition or KO,
supporting AMPK’s role in mediation of resveratrol’s effect and providing evidence that the
AMPKα1 isoform is responsible [72].
2.1.4.4 Retinoic Acid
Retinoic acid (RA) is a metabolite of vitamin A that can regulate gene expression by
binding to retinoic acid receptors (RARs) [76]. The RAR forms a dimer with a retinoid X
receptor (RXR), which then regulates gene expression by binding to RA response elements in the
promoter regions of target genes [77]. In murine brown adipocytes, RA was found to induce a 7fold increase in Ucp1 mRNA levels independently of β-adrenergic pathways and PGC-1α [76].
In mice, a vitamin A-deficient diet resulted in increased body weight, and whole-body fat mass
and decreased Ucp1 expression in iBAT [78]. In mice, treatment with all-trans RA (ATRA) (100
mg/kg body weight) resulted in significant weight loss and increased Ucp1 expression in iBAT,
regardless of whether the mice were on a vitamin A-deficient or regular chow diet [78].
Although RA is a potent positive regulator of BAT activity in mice, similar effects are unlikely
in humans based on the observation that ATRA inhibits or has no effect on UCP1 expression in
human adipocyte cell lines and primary human white adipocytes [77].
12

2.1.4.5 Pharmacological Agents
Several pharmacological agents with the ability to regulate BAT activity are also under
investigation, many of which mimic nutritional regulators in their mechanisms of action [57].
For example, a specific AMPK activator, A-769662, has been found to activate BAT similarly to
resveratrol and is being explored for its therapeutic potential in the treatment of type 2 diabetes
[72, 79]. A handful of these drugs have reached human trials, many of which are β3-AR agonists
[8]. β3-AR agonists are currently used for the treatment of overactive bladder in humans [80]. Of
the β3-AR agonists that have been studied for BAT activation in humans, rafabegron,
mirabegron, and ZD2079 have had somewhat positive results. Rafabegron, or TAK-677,
promoted a slight increase in energy expenditure at the highest dose (0.5 mg twice daily for 29
days) in obese men and women; however, heart rate was elevated at this dose, and there were no
changes in weight, body composition, or fasting insulin, FFA, or glucose concentrations [81].
ZD2079 (600 mg twice daily for 14 days) was studied in obese men and women and was also
found to slightly increase energy expenditure [82]. In a study of healthy men, a single dose of
200 mg mirebegron was found to significantly increase BAT metabolic activity as measured by
[18F]FDG-PET/CT in all subjects and increase resting metabolic rate by an average of 203
kcal/day [83]. Treatment also increased heart rate and systolic, but not diastolic, blood pressure
[83]. These increases were less than what has been reported for other sympathomimetics and
there were no unanticipated adverse effects [83, 84]. Cardiovascular side effects are a concern
for all β3-AR agonists since β3-AR is expressed in the human heart [85].
Pharmacological strategies for increasing norepinephrine are also being explored as a
means of increasing BAT activity via adrenergic stimulation. Ephedrine increases
13

norepinephrine release and acts as an adrenergic receptor agonist itself [86]. In humans, 2.5
mg/kg body weight of ephedrine increased BAT activation as measured by [18F]FDG-PET/CT in
lean but not obese individuals, resulting in a mean increase in energy expenditure of 18% in the
lean individuals [84]. Ephedrine also significantly increased systolic blood pressure, heart rate,
and blood glucose in lean and obese subjects as well as diastolic blood pressure in lean subjects
[84]. Atomoxetine is a drug currently marketed for the treatment of attentiondeficit/hyperactivity disorder (ADHD) that inhibits norepinephrine reuptake by blocking the
presynaptic norepinephrine transporters, thereby prolonging activation of postsynaptic β3-AR
[87]. Rats treated with 0.1 mg/kg body weight of atomoxetine displayed increased [18F]FDG
uptake by iBAT, which was significantly blunted by propranolol, a β-adrenergic antagonist [87].
In obese women instructed to follow a calorie-restricted diet, atomoxetine treatment (100
mg/day) resulted in a slightly greater decrease in weight and waist circumference as compared to
women receiving a placebo, but the involvement of BAT activity was not investigated [88].
Non-adrenergic regulators of BAT, such as melanocortins, glucocorticoids, natriuretic
peptides, and a variety of lipokines, are being investigated as potential therapeutic targets as well
[89, 90]. Some of these regulators may be useful applied as pharmacologic agents themselves,
while others are being exploited as drugs that mimic the mechanisms of action or manipulate the
concentrations of positive regulators of BAT activity [90]. For example, multiple strategies are
being used to develop the most effective pharmacological method of increasing circulating levels
of FGF21, an endocrine hormone that regulates energy homeostasis and insulin sensitivity which
is thought to be at least partly accomplished via BAT regulation [91, 92]. These strategies
include PEGylated FGF21, FGF21-antibody conjugates, and antibody-based activation of the
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fibroblast growth factor (FGFR)/β-Klotho complex [93-95]. FGF21 analogs LY2405319 and PF05231023 have been studied in humans. PF-05231023 administration to obese cynomolgus
monkeys and human patients with type 2 diabetes resulted in significant weight loss and an
improved lipid profile with no significant changes in glucose [94]. Similarly, LY2405319
treatment of obese, diabetic patients showed improvements in lipid levels and fasting insulin and
decreased bodyweight with no changes in glucose [96]. While much progress has been made, the
development of an effective agent for BAT activation with minimal side effects is an ongoing
endeavor that warrants further efforts.
2.2 Overview of sEH Inhibitors
2.2.1 Introduction to sEH
Soluble epoxide hydrolase (sEH) is a homodimeric enzyme with two functionally
different domains [97]. The C-terminal domain is a hydrolase that catalyzes the conversion of
EpFAs to dihydroxy fatty acids (DiHFAs), also known as diols, while the N-terminal domain is a
phosphatase for which neither the endogenous substrate nor physiological role has been fully
elucidated [10, 11, 97, 98]. EpFAs include the EETs generated by cytochrome P450 (CYP450)
from arachidonic acid as well as the CYP450 products of other polyunsaturated FFAs such as
linoleic acid, DHA, and EPA [11, 99]. Many of the EpFAs and their diols are biologically active
and affect several biological processes [11, 14, 99-101]. EpFAs can be metabolized by several
different pathways, but sEH is the predominant pathway in many tissues [11]. In humans, sEH is
encoded by the EPHX2 gene and expressed widely throughout the body: identified in the liver,
kidney, brain, muscles, prostatic ducts, gastrointestinal tract, epithelial cells, and in certain
endocrine and lymphatic tissues [102-104]. In some tissues, such as the liver, sEH expression is
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broadly distributed while in other tissues, such as the kidney and brain, expression is localized to
specific regions [100, 103].
Several factors have been found to regulate sEH expression or activity, with evidence of
some tissue-and sex-specific regulation [105-108]. For example, in mice, PPARγ agonists have
been seen to induce sEH expression in adipose tissue, but not in the liver, and downregulate sEH
in cardiomyocytes [106, 107]. sEH also appears to be regulated by sex hormones, with
testosterone increasing and estrogen decreasing sEH activity [109, 110]. Other regulators that
have been identified include angiotensin II, reactive oxygen species, homocysteine, and PPARα
agonists to name a few [106, 111-115].
2.2.2 sEH and Metabolic Disease
sEH has been studied in relation to a variety of biological processes and disease states
[13]. In general, the EpFA precursors of sEH metabolism, especially the EETs, are antiinflammatory and have a higher biological activity than the diol products of sEH, of which some
are actually pro-inflammatory [11, 101]. Because of this, a majority of the current sEH research
focuses on the beneficial effects of inhibition of the sEH hydrolase domain [13]. In various
animal models, sEH inhibitors (sEHIs) and sEH KO have been found to be protective against
many conditions, such as aortic aneurysm, atherosclerosis, stroke, heart attack, arrhythmia,
chronic obstructive pulmonary disease, pulmonary hypertension, hypertension-induced organ
damage, inflammation, and inflammatory and neuropathic pain [13]. sEH KO and inhibition
have also shown to be beneficial for several aspects of metabolic disease [14], which will be
discussed further here.
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To begin, sEH has been investigated for its role in insulin resistance, a major risk factor
in metabolic disease [13, 116-118]. Treatment with the sEHI t-AUCB or sEH KO was found to
prevent hyperglycemia and augment glucose-stimulated insulin secretion in pancreatic islet cells
in mice with streptozotocin-induced diabetes [118]. Diabetic sEH KO mice also had improved
glucose tolerance, increased insulin secretion during a hyperglycemic clamp study, and reduced
islet cell apoptosis as compared to diabetic WT mice [118]. Another study found that in mice
with HFD-induced obesity and type 2 diabetes, sEH KO or inhibition by sEHI TUPS (1-(1methylsulfonyl-piperidin-4-yl)-3-(4-trifluoromethoxyphenyl)-urea) significantly decreased
plasma glucose levels and increased pancreatic islet size and vasculature as compared to WT
mice without sEHI treatment [117]. Additionally, sEH KO resulted in increased insulin
sensitivity and insulin receptor signaling in the liver [117]. EETs are known to improve insulin
resistance, which is thought to be mediated by activation of insulin receptor signaling and
adiponectin-mediated AMPK signaling pathways as well as upregulation of nitric oxide synthase
expression [14]. This suggests that the observed effects of sEH KO or inhibition on insulin
resistance are, at least in part, mediated by the increase in EETs that has been shown to occur
with both sEH KO and inhibition in mice [14, 119].
sEH also plays a part in lipid metabolism, another key factor in metabolic disease [120].
In rats fed a high carbohydrate, high fat (HCHF) diet, t-AUCB treatment attenuated increases in
total cholesterol and non-esterified fatty acids that were seen in control HCHF rats [121]. In
adipocytes, t-AUCB treatment upregulated ATP-binding cassette transporter A1 (ABCA1),
thereby improving cholesterol efflux, and increased CD36-mediated degradation of oxidized
LDL (low-density lipoprotein) [121]. In mice, sEH KO was seen to decrease plasma cholesterol
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by about 25% and decrease liver expression of HMG-coA reductase by approximately 2-fold as
compared to WT mice [119]. Interestingly, further exploration revealed opposite roles of the two
sEH domains in regulating cholesterol levels, with overexpression of human sEH phosphatase
only in HepG2 cells leading to elevated cholesterol levels, while overexpression of sEH
hydrolase only led to lowered cholesterol levels [119]. Consistent with these findings, TUPS
treatment of WT mice and HepG2 cells expressing human sEH resulted in elevated cholesterol
levels [119].
Non-alcoholic fatty liver disease (NAFLD) is a condition associated with obesity that
may benefit from sEH KO or inhibition, which were both shown to alleviate HFD-induced
hepatic steatosis in mice [122]. This effect could involve direct inhibition of sEH in the liver as
well as the reduction in systemic inflammation observed with sEH inhibition by t-AUCB [122].
A more recent study reported similar findings and further added that sEH KO or inhibition with
TPPU (1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea) or t-TUCB (trans-4-{4-[3(4-trifluoromethoxy-phenyl)-ureido]-cyclohexyloxy}-benzoic acid) also suppressed expression
of genes involved in lipid synthesis and increased expression of Ppara, a regulator of βoxidation, which can explain the suppression of fat accumulation in the liver [123].
Although several studies have demonstrated benefits of sEH inhibition on obesityassociated diseases, the relationship between sEH and obesity itself is less clear [14]. sEH
expression increases upon differentiation in both white [106] and brown (unpublished data)
adipocytes. Moreover, in vitro and in vivo induction of adipogenesis was seen to decrease
adipose-derived EETs, likely indicating increased sEH activity, while administration of stable
EET analog (S)-2-(11-(nonyloxy)undec-8(Z)-enamido)succinic acid (NUDSA) or EET-A to
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HFD-fed mice resulted in significantly less weight gain, adipose tissue expansion, and mRNA
expression of proadipogenic genes in WAT and increased Ucp1 mRNA expression in BAT [15].
In HFD-fed mice, sEH inhibition by AR9281 1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-ylurea) promoted significant weight loss by reducing appetite and increasing metabolic rate, which
may be mediated to some degree by BAT, as evidenced by an approximately 50% increase in
BAT UCP1 expression in treated mice [16]. However, conflicting results of no effect of sEH
inhibition on weight gain in HCHF diet-fed rats or HFD-fed mice have also been reported [121,
122]. These discrepancies may be due to the differences in animal models, sEHI, or doses used.
We have found sEH mRNA to be significantly upregulated in BAT but not epididymal
white adipose tissue (eWAT) or inguinal white adipose tissue (iWAT) in HFD-induced obese
mice. In vitro studies have revealed that sEH inhibition by t-TUCB or t-AUCB dose-dependently
promotes murine brown adipocyte differentiation (t-AUCB more robustly than t-TUCB), as
demonstrated by lipid accumulation visualized by Oil Red O staining and mRNA and protein
expression of brown marker genes UCP1 and PGC-1α (unpublished data).
Taken together, these data support the therapeutic potential of sEH inhibition for
metabolic disease. Thorough mechanistic studies of sEHIs and sEH metabolites are still needed
so that findings in animal models can be translated to the treatment of human conditions.
2.2.3 sEH Inhibitors
The catalytic activity of the sEH hydrolytic domain has been targeted by mimics of the
reaction intermediates and transition states, which serve as inhibitors of the enzyme [10]. A
variety of low-nanomolar to picomolar inhibitors were developed following the discovery of
dicyclohexyl urea as a reversible sEHI that binds to the sEH active site by mimicking the
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reaction intermediate [124, 125]. These inhibitors have a primary urea central pharmacophore
and studies of the structure-activity relationship of sEHIs revealed that they should have a small
group such as a phenyl or hexyl on one side but can have a larger group on the opposite side
[126].
AUDA (12-(3-adamantan-1-yl-ureido) dodecanoic acid), is an sEHI that was designed to
mimic fatty acid substrates of sEH and has been found to be a PPARα ligand [22, 25]. AUDA is
also rapidly metabolized in vivo due to its susceptibility to CYP450 oxidation and β-oxidation
[22]. Even with these limitations, AUDA treatment has yielded positive results in many animal
studies [127, 128]. Following the discovery that a polar group called the secondary
pharmacophore can be positioned 5-7 atoms from the primary pharmacophore without affecting
the potency of the sEHI, sEHIs with improved physical properties were developed [17]. In most
of the more recently developed sEH inhibitors, the secondary pharmacophore is typically an
ether, as seen in AEPU (1-adamantanyl-3-{5-[2-(2-ethoxyethoxy)ethoxy]pentyl]} urea), a
heterocycle, or an amide [17].
The replacement of the alkyl chain present in AUDA and AEPU with a conformationally
restricted molecule such as piperdine, cyclohexyl, or phenyl has further improved the potency
and pharmacokinetics of sEH inhibitors in multiple species [129]. These inhibitors include
TPPU, APAU (1-(1-acetypiperidin-4-yl)-3-adamantanylurea), TPAU (1-trifluoromethoxyphenyl3-(1-acetylpiperidin-4-yl) urea), t-AUCB and its cis-isomer c-AUCB, t-TUCB, sorafenib (4-[4({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2carboxamide), t-CUPM (trans-4-{4-[3-(4-chloro-3-trifluoromethyl-phenyl)-ureido]cyclohexyloxy}-pyridine-2-carboxylic acid methylamide) and others [13, 17].
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Two sEHIs have entered human clinical trials so far: GSK2256294 ((1R,3S)‐N‐(4‐cyano‐
2‐(trifluoromethyl)benzyl)‐3‐((4‐methyl‐6‐(methylamino)‐1,3,5‐triazin‐2‐
yl)amino)cyclohexanecarboxamide), for treatment of diabetes, pulmonary obstructive disease,
and subarachnoid hemorrhage, and AR9281, for treatment of hypertension and impaired glucose
tolerance [19, 20]. GSK2256294 is an sEHI that has been tested in two phase I trials where it was
studied in healthy males, obese male smokers, and healthy elderly males and females for its
safety, pharmacokinetics, and effects on biliary metabolites [19]. GSK2256294 (2-20 mg) was
well‐tolerated with no serious adverse events and demonstrated sustained dose-dependent
inhibition of sEH, regardless of age or gender [19]. AR9281 has also been studied in phase I
trials in healthy men and women with no serious adverse events and sustained inhibition of sEH
when multiple doses (400 mg every 8 hours) were administered [20]. The initial results of these
trials, determining that two structurally very different sEHIs are safe for human treatment.
However, the efficacy of sEHIs in treating human diseases is yet to be reported.
2.3 sEH Inhibitor t-AUCB: Current Applications and Opportunities
2.3.1 t-AUCB Structure, Bioavailability, and Efficacy
t-AUCB is one of the more recently developed conformationally restricted sEHIs. The
structure of t-AUCB is a disubstituted urea central pharmacophore with an N-adamantyl group,
and an N’-trans-1,4 cyclohexane ring serving as a link to benzoic acid. t-AUCB was designed in
an effort to optimize sEHIs by testing the trans- and cis-isomers of several different compounds
generated by the addition of a polar group to the cyclohexane ring of the base structure Nadamantyl-N′-cyclohexylurea (ACU). t-AUCB and c-AUCB were found to have dramatically
increased water solubility and metabolic stability as well as relatively high inhibitor potencies as
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compared to the other compounds developed. In general, the cis-isomers tested were less stable
than the trans-isomers, likely because the trans-isomers were less susceptible to metabolism by
CYP450s [18].
The pharmacokinetics of the ACU-derived compounds were studied by oral
administration of 0.3 mg/kg to dogs, which have been shown to have very similar gastrointestinal
absorption to humans [18, 130]. The area under the curve (AUC) estimated for inhibitor plasma
concentration versus time was found to be highest for t-AUCB, which had a 40-fold increase
compared to AUDA and a 4-fold increase compared to APAU[18]. The oral bioavailability of tAUCB was also assessed by comparing plasma concentrations over 24 hours following oral
versus intravenous administration in dogs; oral bioavailability was determined to be 98% with a
Tmax of 8 hours and a T1/2 of 19 hours [18].
The potency of t-AUCB for mouse, rat, hamster, cat, dog, and human sEH was
determined by fluorescent or radioactive assays. Unlike other sEHIs, t-AUCB was a potent sEHI
regardless of the animal species of origin of sEH. Moreover, t-AUCB had an IC50 of only 2 nM
for human sEH. Finally, t-AUCB was seen to normalize lipopolysaccharide-induced hypotension
in mice with a 10-fold lower dose than what was needed for the prodrug of AUDA, AUDA-BE
(12-(3-adamantan-1-ylureido)dodecanoic acid butyl ester), to have similar effects. t-AUCB
appears to be one of the most promising sEHIs due to its water solubility, stability,
bioavailability, and efficacy across species [18].
2.3.2 Current Applications of t-AUCB
In addition to the aforementioned metabolic studies that utilized t-AUCB for sEH
inhibition [2.2.2], t-AUCB has been applied to a variety of disease models [131-140]. The effects
22

of t-AUCB on renal function have been studied in rodents [131-134]. In mice, oral
administration of t-AUCB resulted in fibroprotective and anti-inflammatory effects similar to
sEH KO [131, 132]. In rats with streptozotocin-induced diabetes, t-AUCB attenuated renal injury
by reducing albumin, glomerular albumin permeability, and nephrin excretion while restoring
glomerular α3 integrin and nephrin expression [133]. t-AUCB treatment of spontaneously
hypertensive obese rats reversed the increase in urinary levels of albumin and kidney injury
marker-1 (KIM-1) and co-administration of t-AUCB with PPARγ agonist rosiglitazone resulted
in enhanced reno-protection [134].
The cardiovascular implications of t-AUCB have been studied in mice [135, 136].
Infusion of isolated mouse hearts with t-AUCB resulted in improved postischemic contractile
function and reduced infarct size which was shown to be mediated through EETs and the
phosphatidylinositol 3-kinase (PI3K) pathway [135]. In a mouse model of myocardial infarction
(MI), treatment with t-AUCB for 7 days prior to MI resulted in reduced infarct size, improved
cardiac function, prevention of cardiac arrhythmias, and suppression of muscle-specific
microRNA-133, a small noncoding RNA that interferes with the expression of arrhythmiarelated genes [136].
t-AUCB has also been examined in relation to inflammation [137, 138]. In a
lipopolysaccharide-challenged murine model, it was found to enhance the anti-inflammatory
effects of aspirin, a cyclooxygenase (COX) inhibitor, or MK886, a 5-lipoxygenase activation
protein (FLAP) inhibitor [137]. t-AUCB also attenuated the development of inflammatory bowel
disease in IL-10 KO mice (a mouse model of IBD), evidenced by a lower incidence of ulcer
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formation and transmural inflammation as well as a significant decrease in inflammatory signals
and neutrophil infiltration to the bowel [138].
Human studies of t-AUCB are still limited to in vitro work. In human glioblastoma cell
lines U251 and U87, t-AUCB dose-dependently suppressed cell growth, likely via activation of
NF-κB [139]. Furthermore, t-AUCB treatment induced G0/G1 phase arrest by regulation of
Cyclin D1 and phosphorylated-CDC2 levels [139]. In endothelial progenitor cells from patients
with acute MI, t-AUCB dose-dependently promoted angiogenesis and migration and increased
expression of angiogenic factors in a PPARγ-dependent manner [140].
2.3.3 Research Gap
In summary, soluble epoxide hydrolase (sEH) is a cytosolic enzyme that converts epoxy
fatty acids (EpFAs) into less active diols. By stabilizing endogenous EpFAs, potent small
molecule sEH inhibitors have been shown to be beneficial for many diseases. Two sEHIs have
entered human trials and appear to have minimal adverse effects. Our preliminary results have
shown that sEH expression was increased during both murine and human brown adipocyte
differentiation and that t-AUCB treatment dose-dependently induced murine adipocyte
differentiation.
The purpose of this thesis is to explore the mechanisms by which t-AUCB promotes
brown adipogenesis, specifically the role of PPARα and PPAR in t-AUCB-induced brown
adipogenesis, to improve our understanding of the inhibitor, its effects reported thus far, and its
potential applications.
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CHAPTER III
MATERIALS AND METHODS
3.1 Reagents
sEH inhibitor t-AUCB was synthesized as previously described [129, 141]. PPARγ
antagonist GW9662, PPARα antagonist GW6471, and PPARα agonist WY-14643 were
purchased from Cayman Chemical (Ann Arbor, MI). PPARγ agonist rosiglitazone was
purchased from Sigma-Aldrich (St. Louis, MO). Dimethyl sulfoxide (DMSO) was purchased
from Acros Organics (Thermo Fisher Scientific, Pittsburg, PA). Anti-UCP-1, anti-FABP4, antiβ-Actin, anti-PPAR, anti-ERK1/2, horseradish peroxidase-conjugated goat anti-rabbit, and
horseradish peroxidase-conjugated goat anti-mouse antibodies were purchased from Cell
Signaling Technology (Danvers, MA). Anti-PGC-1α antibody was purchased from Millipore
(Temecula, CA). Anti-PPARα and anti-α Tubulin antibodies were purchased from Santa Cruz
Biotechnology (Dallas, TX). Anti-sEH antibody was generated and used as described previously
[142, 143].
3.2 Cell Culture and Differentiation
The murine brown preadipocyte cell line was a gift from Dr. Johannes Klein (University
of Lubeck, Lubeck, Germany). This cell line was generated from the interscapular brown fat of
newborn C57BL/6 mice [144]. Brown fat cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 20% fetal bovine serum (FBS) (Atlanta Biologicals,
Flowery Branch, GA) in a humidified 37 °C and 5 % CO2 incubator until they reached
confluence (designated as day 0). The cells were induced to differentiate by treatment with
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differentiation media consisting of DMEM supplemented with 20% FBS, 1 nM T3, and 20 nM
insulin. Media was replaced every 2 days for 6 days.
Murine sEH WT and sEH KO BAT stromal cells were a gift from Dr. Ahmed Bettaieb
(University of Tennessee, Knoxville). Cell lines were generated from mouse primary stromal
cells that were isolated from the BAT of sEH (encoded by Ephx2 gene) WT and KO mice as
previously described [145]. The day after isolation (day 1), media was replaced with fresh
DMEM supplemented with 20% FBS. On day 3, cells were washed with PBS (phosphatebuffered saline) and media was replaced. Cells were again washed and media changed on day 5.
On day 6, cells were trypsinized and reseeded for infection with a lentivirus encoding large T
antigen and NeoR gene in crude media for 24 hours. After 24 hours, media was changed back to
DMEM with 20% FBS. 48 hours later, media was replaced with selection media of FBS, 20%
FBS, and 600 μg neomycin. Cells were maintained in selection media for 2 weeks. For
differentiation, the sEH WT and sEH KO cells were grown in DMEM supplemented with 20%
FBS until they reached confluence. The cells were induced for 3 days with induction media
consisting of differentiation media (DMEM with 20% FBS, 1 nM T3, and 20 nM insulin)
supplemented with 0.125 mM indomethacin, 5 µM dexamethasone, and 0.5 mM 3-isobutyl-1methylxanthine. Cells were then switched to differentiation media for an additional 3 days.
Media was replaced every 2 days.
3.3 Lentiviral shRNA Particle Infection
Murine brown preadipocyte cells were plated at ~50% confluence in 6-well plates. The
cells were then infected with MISSION Lentiviral Transduction Particles for mouse Ppara,
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Pparg, or scrambled non-targeting control according to the manufacturer’s instructions (SigmaAldrich). Stably infected cells were selected by puromycin (40 μg/ml) for two weeks.
3.4 Western Blot Analysis
Total cell lysates were prepared using 1X lysis buffer (Cell Signaling, Danvers, MA) and
protein concentrations were determined using the BCA assay kit (Thermo Scientific, Waltham,
MA). Proteins were separated on a 10% SDS-PAGE then transferred to polyvinylidene
difluoride membranes (Bio-Rad, Hercules, CA). The membranes were blocked in TBST buffer
(20 mM Tris Base, 137 mM NaCl, and 0.1% Tween 20 (pH 7.4)) containing 5% nonfat milk.
Membranes were then immunoblotted with the indicated primary antibodies at 4°C overnight
followed by 1-hour incubation with secondary antibodies conjugated with horseradish
peroxidase. Proteins were visualized using ECL Western Blot detection reagent (Pierce,
Rockford, IL). Densitometry of bands was quantified using ChemiDocXRS+ imaging system
and analyzed using ImageLab software (Bio-Rad).
3.5 RNA Preparation and Quantitative Real-Time PCR Analysis
Total RNA was isolated using TRI reagent (Molecular Research Center, Cincinnati, OH)
according to the manufacturer’s instructions. Total RNA was quantified using NanoDrop ND1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). Reverse transcription was
carried out using High Capacity cDNA Reverse Transcription kit (Thermo Scientific, Pittsburgh,
PA) according to the manufacturer’s instructions. mRNA expression of target genes and the
housekeeping gene 36B4 (a ribosomal protein that is a component of the 60S subunit) was
measured quantitatively using PowerUp SYBR master mix (Applied Biosystems, Austin TX).
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PCR reactions were run in a 96-well format using an ABI 7300HT instrument. Cycle conditions
were 50°C 2 min, 95°C 10 min, 40 cycles of 95°C for 15 s, then 60°C for 1 min. Relative gene
expression was calculated using the 2-ΔΔCt method, after normalization to the housekeeping gene
36B4. Primer sequences are available upon request.
3.6 Reporter Gene Assays
Murine brown preadipocytes seeded on 24-well plates were transiently transfected with
murine PPAR or PPARα transactivation reporters and -galactosidase expression plasmid with
Lipofectamine 3000 Transfection Reagent and Plus Reagent (Thermo Fisher Scientific, Carlsbad,
CA). Murine sEH KO and sEH WT brown preadipocytes were transiently transfected with
murine PPAR or PPARα transactivation reporters and -galactosidase expression plasmid with
Viafect Transfection Reagent (Promega, Madison, WI.). PPAR transactivation reporters consist
of murine PPARγ ligand-binding domain ligated to the Gal4 DNA-binding domain (DBD)
(mPPARγ-Gal4) and a reporter construct containing an upstream activating sequence (UAS)–
linked luciferase, 4xUAS-TK-luc (TK: thymidine kinase). PPARα transactivation reporters
consist of murine PPARα ligand-binding domain ligated to the Gal4 DNA binding domain
(DBD) (mPPARα-Gal4) and 4xUAS-TK-luc. Both reporters were gifts from Dr. Susanne
Mandrup (University of Southern Denmark, Denmark) [146]. 24 hours post-transfection, the
murine brown preadipocytes were treated with vehicle control DMSO or sEH inhibitor t-AUCB
and DMSO, GW6471, or GW9662 for 18 hours. sEH WT and sEH KO cells were treated with
DMSO or t-AUCB for 18 hours. Cell lysates were prepared, and reporter luciferase and galactosidase activities were measured with GloMax Luminometer (Promega, Madison, WI).
Relative luciferase activities were normalized to -galactosidase activities.
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3.7 Statistical Analysis
Statistical analysis was performed using SigmaPlot 14.0 (Systat Software, Inc.). One-way
ANOVA with repeated measures followed by multiple group-wise comparisons (StudentNewmanKeuls Method) was performed to determine the differences among the treatment groups
(e.g., doses). The level of significance was set at p< 0.05.
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CHAPTER IV
RESULTS AND DISCUSSION
4.1 Results
4.1.1 Effects of t-AUCB on murine brown adipocyte differentiation
First, the effects of t-AUCB on murine brown adipocyte differentiation were examined.
Lipid accumulation murine brown preadipocytes differentiated in the presence of t-AUCB was
visualized by Oil Red O staining, which showed a dose-dependent increase in lipid accumulation
with t-AUCB treatment (Fig. 1B). mRNA expression of marker genes of thermogenesis and
differentiation in the differentiated cells was also seen to increase in response to t-AUCB in a
dose-dependent manner, reaching significant levels for Pparg and Cidea at 5 µM or above and
for Ucp1, Pgc-1a and Fabp4 at 10 µM or above (Fig. 1C).
4.1.2 t-AUCB activates PPARα, but not PPARγ
To study the roles of PPARs in mediating the observed effects of t-AUCB, respective
PPAR transactivation reporter assays were performed in a murine brown preadipocyte cell line.
In cells transfected with PPARα or PPARγ reporters, t-AUCB activated PPARα, but not PPARγ,
and this activation was eliminated by cotreatment with PPARα antagonist GW6471 (Fig. 2).
PPAR agonist rosiglitazone produced a ~55-fold increase in PPAR activation, which was
completely attenuated by GW9662 (Fig. 2). There was no activation of PPARα by rosiglitazone
(Fig. 2). PPARα agonist WY-14643 produced a ~2.7-fold increase in PPARα activation, which
was completely attenuated by GW6471 (Fig. 2). There was no activation of PPAR by WY14643.
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4.1.3 t-AUCB-induced upregulation of mRNA markers of thermogenesis and
differentiation is attenuated by PPARα antagonist GW6471.
The role of PPARs in t-AUCB’s effects was studied using PPAR antagonists. The
observed upregulation of Ucp1, Pparg, Pgc-1a, and Fabp4 in differentiated murine brown
adipocytes was attenuated by cotreatment with GW6471, compared to cotreatment with DMSO
(Fig. 3). In contrast, GW9662 treatment caused an overall decrease in Ucp1, Pparg, Pgc-1a, and
Fabp4 expression, but the dose-dependent increases of these genes by t-AUCB were maintained
(Fig 3). Treatment with WY-14643 upregulated Ucp1, Pparg, Pgc-1a, and Fabp4 to a similar
extent as t-AUCB, and this upregulation was attenuated by GW6471 and, to a lesser extent,
GW9662 (Fig. 3). Rosiglitazone significantly increased Ucp1, Pgc-1a, and Fabp4 expression in
DMSO, which was attenuated by GW9662, but enhanced by GW6471 (Fig. 3). Pparg expression
was significantly decreased with rosiglitazone and DMSO or GW9662 treatment but
significantly increased with rosiglitazone and GW6471 (Fig. 3).
4.1.4 t-AUCB-induced upregulation of mRNA and protein markers of thermogenesis and
differentiation is attenuated by PPARα knockdown.
The role of PPARs in t-AUCB’s effects were further studied by respective PPAR
knockdown. The murine brown preadipocytes were infected with scramble (control), Ppara KD,
or Pparg KD lentivirus, and stable individual KD clones and control clones were selected by
antibiotics and expanded for further analysis. The efficiency of knockdown of PPARα and
PPARγ was first confirmed by Western Blot analysis. As shown in Fig. 4, a 60-80% decrease in
PPARα and PPARγ protein expression was achieved in each of the two selected PPARα KD and
PPARγ KD clones, respectively, as compared to the control clones (Fig. 4A). There was no
significant difference in average PPARα expression between the PPARγ KD clones and the
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control clones, but there was a slight but significant increase in average PPARγ expression in the
PPARα KD clones compared to the control clones (Fig. 4A).
PPARα KD and, to a greater extent, PPARγ KD resulted in decreased mRNA expression
of Ucp1, Cidea, and Pgc-1a across all treatments as compared to the control (Fig. 4B). t-AUCBinduced dose-dependent upregulation of Ucp1 and Cidea was significantly attenuated by PPARα
KD and to a greater degree by PPARγ KD as compared to the control (0) of each respective
treatment group (Fig. 4B). t-AUCB-induced dose-dependent upregulation of Pgc-1a and Fabp4
was almost completely attenuated by PPARα KD but not PPARγ KD (Fig. 4B). Interestingly,
PPARγ KD also decreased Fabp4 expression across all treatments as compared to the control
treatment group, but PPARα KD increased Fabp4 expression by up to nearly 10-fold (Fig. 4B).
Upregulation of Ucp1, Cidea, Pgc-1a, and Fabp4 by WY-14643 was attenuated by PPARα KD
(Fig. 4B). With PPARγ KD, WY-14643 still significantly increased expression of Ucp1, Pgc-1a,
and Fabp4, but did not significantly affect Cidea expression (Fig. 4B). Rosiglitazone
significantly increased expression of Ucp1, Cidea, Pgc-1a, and Fabp4 (Fig. 4B). Upregulation of
Ucp1 and Cidea by rosiglitazone was attenuated by PPARγ KD, but upregulation of Pgc-1a and
Fabp4 was unchanged and further enhanced, respectively, by PPARγ KD (Fig. 4B). Relative to
the control (0) of each treatment group, PPARα KD attenuated rosiglitazone to a greater extent
than PPARγ KD in all four genes (Fig. 4B).
Similar patterns were seen in protein expression. PPARα KD, to a greater extent than
PPARγ KD, attenuated upregulation of UCP1, PGC-1α, and FABP4 by t-AUCB (Fig. 4C).
Relative to the control (0) of each treatment group, PPARα KD completely eliminated t-AUCBinduced upregulation of PGC-1α and FABP4 (Fig. 4C). An increase in UCP1 with t-AUCB was
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still evident with PPARα KD, but the degree of UCP1 stimulation by t-AUCB with PPARα KD
was much less than with PPARγ KD (Fig. 4C). FABP4 protein expression, like mRNA
expression, was significantly increased with PPARα KD across all treatments as compared to the
control treatment group (Fig. 4C).
4.1.5 t-AUCB activates PPARα independent of sEH.
To further understand the mechanisms underlying t-AUCB’s effects, the response to tAUCB was compared between BAT derived stromal cell lines from sEH WT and KO mice. sEH
expression in WT cells was significantly greater than KO cells at both day 0 and day 7, with sEH
expression in KO cells being only 12% of WT on day 7 (Fig. 5A). There was no difference in
Tubulin expression between sEH WT or KO cells at day 0 and the expression was diminished at
day 7 in both cell lines, demonstrating similar differentiation capacities between the WT and KO
cells (Fig. 5A). WY-14643 and rosiglitazone induced ~ 3-fold increase in PPARα activation and
~18-fold increase in PPAR activation, respectively, in sEH WT cells (Fig. 5B). t-AUCB
activated PPARα to a similar extent in sEH WT compared to that in sEH KO cells (Fig. 5B).
Consistently, t-AUCB did not significantly activate PPAR in sEH WT or sEH KO cells (Fig.
5B).
4.2 Discussion
Accumulating evidence supports the involvement of sEH in metabolic diseases and the
beneficial effects of sEHIs. sEH has been studied in WAT differentiation [106] and obesity [14,
16], but the role of sEH and the effects of its inhibition in brown adipogenesis are not known. To
our knowledge, the current study is the first to demonstrate the effects of sEHI t-AUCB on
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cellular brown adipogenesis and explore the roles of PPARα and PPARγ. Previously reported
metabolic effects of t-AUCB include improved insulin secretion in mice with streptozotocininduced diabetes [118], attenuation of increases in total cholesterol in HCHF-fed rats [121], and
upregulation of ABCA1 in adipocytes [121]. The mechanisms of the effects of t-AUCB, and
sEHIs in general, are not well defined [21]. The presumed underlying mechanism of most of the
observed sEHI effects is the accumulation of EETs or other biologically active EpFAs that can
occur with sEH inhibition [21]. There is evidence of the existence of a high-affinity EET Gprotein-coupled receptor, but this has not been fully characterized [147-149]. Several EET
receptors and binding sites have been identified, including FABP [150], cannabinoid receptor
[151], dopamine receptor [151], prostaglandin E (EP2) receptor [152], PPARα [23], and PPARγ
[24]. The ability of EETs to bind PPARα and PPARγ are of particular interest to us, due to the
involvement of these transcription factors in adipogenesis.
The ability of EETs to bind PPARs may explain the reported proadipogenic effects in
WAT and increases in UCP1 expression in BAT seen with NUDSA or EET-A treatment [153].
PPARα is expressed primarily in the brown adipose tissue, liver, small intestine, skeletal muscle,
and heart, while PPARγ is expressed in the placenta, large intestine, liver, macrophages, and
other tissues, with expression being highest in white and brown adipose tissues [154, 155].
PPARγ is necessary for and strongly induces both white and brown adipogenesis [39, 40].
PPARγ directly controls genes involved in fundamental adipocyte functions, such as lipid
transport and metabolism, insulin signaling, and adipokine production [155]. Although PPARγ is
expressed in both WAT and BAT, tissue-specific transcription factors and PPARγ coregulators
allow for distinct targeting of each tissue [156]. PPARγ induces UCP1 expression and is required
34

for β-adrenergic signaling-mediated induction of thermogenesis in brown adipocytes as well
[157, 158]. PPARα, while not required for adipogenesis, can also induce significant adipogenesis
[40]. Additionally, PPARα is a characteristic marker of the brown phenotype in adipocytes that
plays a key role in thermogenesis [159]. PPARα regulates lipid catabolism and thermogenic gene
expression via induction of PGC-1α and PRDM16 [159].
We examined the roles of PPARs in t-AUCB’s demonstrated promotion of brown
adipogenesis (Fig. 1). We show that sEH inhibitor t-AUCB activates PPARα, but not PPARγ in
murine brown preadipocytes (Fig. 2). We also demonstrate that the inhibition or knockdown of
PPARα attenuates t-AUCB-induced upregulation of markers of thermogenesis and
differentiation (Fig. 3-4). Furthermore, we show that PPARα activation by t-AUCB is
independent of sEH (Fig. 5). These results suggest that PPARα, more so than PPARγ, plays an
important role in t-AUCB’s effects in cellular brown adipogenesis and that these effects may not
depend on sEH.
The exact mechanism by which t-AUCB activates PPARα warrants further investigation.
sEHIs were designed to mimic the epoxide substrates of sEH [22], of which several have been
found to activate PPARα [23, 160]. In transient transfection assays conducted in rabbit kidney
epithelial cell line RK13 cells. 1 µM of the omega-alcohol of 14,15-EET or a 1:4 mixture of the
omega-alcohols of 8,9- and 11,12-EETs activated human and mouse PPARα [23]. Omegahydroxylated 14,15-EET was reported to bind human PPARα with high affinity, determined by
displacement of cis-parinaric acid from the ligand-binding domain [23]. In transactivation assays
carried out in human liver carcinoma cell line HepG2 cells. 10 μM 11,12-EET, 11,12-EEZE (a
monounsaturated 11,12-EET analog), or 4,15-EET, but not 8,9-EET, activated both PPARα and
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PPARγ [160]. 11,12-DHET and 14,15-DHET, the dihydroxyeicosatrienoic acid (DHET)
products of EET metabolism by sEH, were also found to activate both PPARα and PPARγ [160].
Furthermore, the EETs and DHETs induced mPPARα/RXRα-specific heterodimerization and
subsequent binding to the PPRE site as well as expression of PPARα-responsive genes [160].
Two sEHIs, CUDA and AUDA, have been found to activate PPARα, but not PPARδ or
PPARγ, in PPARα transfected COS-7 cells [25]. CUDA also increased the expression of
carnitine palmitoyltransferase 1A, a PPARα responsive gene, in HepG2 cells [25]. It was
concluded that the ability of these sEHIs to bind and activate PPARα is dependent on the
presence of a carboxylic acid group in their structure; two sEHIs without a carboxylic acid group
that were tested were not able to activate PPARα [25]. Like CUDA and AUDA, t-AUCB
contains a C-terminal carboxylic group [18]. Therefore, it is conceivable that t-AUCB itself may
directly activate PPARα. However, further PPARα binding assays are needed.
It has been reported that in endothelial progenitor cells from patients with acute
myocardial infarction, t-AUCB positively modulated angiogenesis-related function in a PPARγdependent manner [140]. The activation of PPARγ was attributed to t-AUCB’s inhibition of
sEH, leading to an increase in EETs that activate PPARγ [140]. Further evidence was based only
on the observation that PPARγ antagonist GW9662 attenuated t-AUCB’s effects [140]. These
data are compatible with what we report here. We also saw some attenuation by GW9662 in our
study of t-AUCB’s induction of mRNA markers of thermogenesis and differentiation (Fig. 3).
However, this attenuation was minimal compared to that of PPARα antagonist GW6471 and may
be attributable to the ability of GW9662 to also act as a less-potent PPARα antagonist [161].
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To our knowledge, we are the first to explore the mechanisms of t-AUCB in brown
adipogenesis and the first to suggest that a t-AUCB-mediated effect is related to t-AUCB’s sEHindependent activation of PPARα. Our findings are significant for multiple reasons. We show
that t-AUCB is a promising agent for the promotion of brown adipogenesis and may, therefore,
have therapeutic potential for obesity and obesity-related diseases. Additionally, we demonstrate
sEH-independent effects of t-AUCB, which may unmask a confounding variable in many studies
that presume the effects of t-AUCB to be due to sEH inhibition alone. Our findings do not
exclude sEH inhibition as a factor in the promotion of brown adipogenesis. Future research is
needed to study the effects of sEH metabolites on brown adipogenesis as well as to determine the
relative contributions of each mode of action of t-AUCB to the promotion of brown
adipogenesis.
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Figure 1. sEH inhibitor t-AUCB promotes murine brown adipocyte differentiation.
Murine brown preadipocytes were differentiated in the presence of t-AUCB (0, 5, 10, 20 µM) for
6 days. Total RNA samples were isolated and cells were stained on day 6. (A) Chemical
structure of t-AUCB is shown. (B) Oil red O stained cell morphology is shown. (C) mRNA
expression of brown marker genes Ucp1, Pparg, Pgc-1a, and Cidea and general differentiation
marker Fabp4 are shown. Data=Mean±SEM (n=3). *, **, ***, p<0.05, p<0.01, and p<0.001,
respectively, as compared to the control sample (0).
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Figure 2. t-AUCB activates PPARα, but not PPARγ.
Murine brown preadipocytes were transiently transfected with murine (bottom panel) reporters.
The transfected cells were pretreated with DMSO (control), PPARα antagonist GW6471 (10
µM), or PPARγ antagonist GW9662 (30 µM) for one hour. The cells were then treated with
DMSO, GW6471, or GW9662 and t-AUCB (0, 5, 10, 20 µM), PPARα agonist WY-14643 (10
µM), or PPARγ agonist rosiglitazone (1 µM) for 18 hr. Relative luciferase activities were
expressed as fold of the control samples (0) of each treatment group (DMSO, GW6471, or
GW9662). Data=Mean±SEM (n=3). *, **, ***, p<0.05, p<0.01, and p<0.001, respectively, as
compared to the control (0) of each treatment group (DMSO, GW6471, or GW9662). a, b, c,
p<0.05, p<0.01, and p<0.001, respectively, for each treatment within GW6471 or GW9662
treatment groups as compared to its identical treatment within the DMSO treatment groups.
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Figure 3. t-AUCB-induced upregulation of mRNA markers of thermogenesis and
differentiation is attenuated by PPARα antagonist GW6471.
Upon initiation of differentiation, murine brown preadipocytes were pretreated with DMSO
(control), PPARα antagonist GW6471 (10 µM), or PPARγ antagonist GW9662 (30 µM) for one
hour then differentiated in the presence of DMSO, GW6471, or GW9662 and t-AUCB (0, 5, 10,
20 µM), PPARα agonist WY-14643 (10 µM), or PPARγ agonist rosiglitazone (1 µM) for 6 days.
Total RNA samples were isolated on day 6. mRNA expression of brown marker genes Pgc-1a,
Pparg, and Ucp1 and general differentiation marker Fabp4 are shown. Data=Mean±SEM (n=3).
*,**, ***, p<0.05, p<0.01, and p<0.001, respectively, as compared to the control samples (0) of
each treatment group (DMSO, GW6471, or GW9662). a, b, c, p<0.05, p<0.01, and p<0.001,
respectively, for each treatment within GW6471 or GW9662 treatment groups as compared to its
identical treatment within the DMSO treatment group.
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Figure 3 Continued
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Figure 4. t-AUCB-induced upregulation of mRNA and protein markers of thermogenesis
and differentiation is attenuated by PPARα knockdown.
Murine brown preadipocytes were infected with a scramble (control), PPARα KD, or PPARγ
KD lentivirus containing a puromycin resistance gene. The cells were then subjected to
puromycin selection for 2 weeks. Isolated clone and pool samples were collected for protein
analysis. Selected clones were differentiated in the presence of t-AUCB (0, 10, 20 µM), PPARα
agonist WY-14643 (10 µM), or PPARγ agonist rosiglitazone (1 µM) for 6 days. Total RNA and
protein were isolated on day 6. (A) Protein expression of PPARα, PPARγ, and β-Actin (loading
control) of selected control, PPARα KD, and PPARγ KD clones. Bar graphs show normalized
densitometry for PPARα/β-Actin and PPARγ/β-Actin. (B) mRNA expression of brown marker
genes Ucp1, PGC-1a, and Cidea and general differentiation marker Fabp4 are shown. (C)
Protein expression of UCP1, PGC-1α, FABP4, and ERK 1/2 (loading control) are shown. Bar
graphs show normalized densitometry for UCP1/ERK 1/2, PGC-1α/ERK 1/2, and FABP4/ERK
1/2. Data=Mean±SEM (n=3). *,**, ***, p<0.05, p<0.01, and p<0.001, respectively, as compared
to the control samples (0) of each group (control, PPARα KD, or PPARγ KD). a, b, c, p<0.05,
p<0.01, and p<0.001, respectively, for each treatment within PPARα KD or PPARγ KD groups
as compared to its identical treatment within the control group.
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Figure 5. t-AUCB activates PPARα independent of sEH.
Murine sEH WT and sEH KO BAT stromal cells were differentiated for 7 days and protein
samples were collected on day 0 and day 7. sEH WT and sEH KO BAT stromal cells were
transiently transfected with murine PPARα or PPARγ reporters. The transfected cells were
treated with t-AUCB (0, 10, 20 µM), PPARα agonist WY-14643 (20 µM), or PPARγ agonist
rosiglitazone (1 µM) for 18 hr. (A) Protein expression of sEH and tubulin is shown. Bar graphs
show normalized densitometry for Pparα/non-specific band and Pparγ/non-specific band. (B)
Relative luciferase activities are shown as fold of the control samples (0) of each genotype (sEH
WT or sEH KO). Data=Mean±SEM (n=3). *, **, ***, p<0.05, p<0.01, and p<0.001,
respectively. a, b, c, p<0.05, p<0.01, and p<0.001, respectively, for each treatment within the
sEH KO genotype groups as compared to its identical treatment within the sEH WT group.
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